SynthesisNeurocritical care2026
Prognostic Value of Natriuretic Peptides for Delayed Cerebral Ischemia and Outcomes After Aneurysmal Subarachnoid Hemorrhage: An Updated-Systematic Review and Meta-Analysis.
Synthesis in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAneurysmal subarachnoid hemorrhage (aSAH) is a type of hemorrhagic stroke with high morbidity and mortality, with life-threatening secondary complications including delayed cerebral ischemia (DCI). Biomarkers capable of improving early risk of DCI remain understudied. DCI frequently triggers neurogenic cardiac injury, manifested through left ventricular dysfunction and wall strain. Natriuretic peptides (NP), including brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP), have been implicated in the cardiac stress responses after aSAH, but their prognostic utility for DCI remains uncertain.
objectiveThe objective was to systematically review and meta-analyze observational studies evaluating the association of NP with DCI, mortality, and functional outcome in patients with aSAH.
methodsFollowing PRISMA guidelines, five databases were searched up to September 2025. Eligible studies included adult patients with confirmed aSAH and measured NP levels within 7 days, reporting outcomes of interest. Data were synthesized using random-effects models, with effect sizes expressed as odds ratios (ORs) or standardized mean differences (SMDs). Risk of bias was assessed with the ROBINS-I tool.
resultsIn total, 17 studies (n = 3172 patients) were included, with 12 proving data for quantitative synthesis. Elevated NP levels were significantly associated with DCI in dichotomous (OR 2.66, 95% CI 1.16-6.10) adjusted models (adjusted OR (aOR) 1.84, 95% CI 1.01-3.35), and continuous analyses (SMD 0.94, 95% CI 0.20-1.68). Admission NP demonstrated moderate diagnostic accuracy for DCI prediction (pooled area under the curve, AUC, 0.76). In contrast, no statistically significant associations were observed for mortality (OR 2.37, 95% CI 0.66-8.50) or unfavorable functional outcomes (OR 1.90, 95% CI 0.65-5.52). Heterogeneity across studies was substantial.
conclusionsElevated NP levels are significantly associated with DCI in patients with aSAH. These findings support the use of NP as useful prognostic biomarkers. However, their utility in predicting mortality and functional outcomes remains inconclusive. Large prospective studies with standardized methodologies are required to validate their clinical applicability.
Indexed as
Identifiers
42087032What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.